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A B S T R A C T
The prostacyclin analogues, iloprost and treprostinil are extensively used in treating pulmonary
hypertension. Their binding proﬁle and corresponding biochemical cellular responses on human prostanoid
receptors expressed in cell lines, have now been compared. Iloprost had high binding afﬁnity for EP1 and IP
receptors (Ki 1.1 and 3.9 nM, respectively), low afﬁnity for FP, EP3 or EP4 receptors, and very low afﬁnity for
EP2, DP1or TP receptors. By contrast, treprostinil had high afﬁnity for the DP1, EP2and IP receptors (Ki 4.4, 3.6
and 32 nM, respectively), low afﬁnity for EP1 and EP4 receptors and even lower afﬁnity for EP3, FP and TP
receptors. In functional assays, iloprost had similar high activity in elevating cyclic AMP levels in cells
expressing the human IP receptor and stimulating calcium inﬂux in cells expressing EP1 receptors (EC500.37
and 0.3 nM, respectively) with the rank order of activity on the other receptors comparable to the binding
assays. As with binding studies, treprostinil elevated cyclic AMP with a similar high potency in cells
expressing DP1, IP and EP2 receptors (EC500.6, 1.9 and 6.2 nM, respectively), but had low activity at the other
receptors. Activation of IP, DP1 and EP2 receptors, as with treprostinil, can all result in vasodilatation of
human pulmonary arteries. However, activation of EP1 receptors can provoke vasoconstriction, and hence
may offset the IP-receptor mediated vasodilator effects of iloprost. Treprostinil may therefore differ from
iloprost in its overall beneﬁcial pulmonary vasorelaxant proﬁle and other pharmacological actions,
especially in diseases where the IP receptor is down-regulated.
 2012 Elsevier Inc. 
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The endogenous prostanoid, prostacyclin, is of substantial
therapeutic beneﬁt in the treatment of the highly debilitating
disease, pulmonary hypertension [1–4]. Prostacyclin itself is however
chemically unstable at physiological temperatures and pH, and
rapidly decomposes to a relatively inactive breakdown product as
reviewed by Whittle and colleagues [5,6]. Therefore, the early clinical
use of prostacyclin, as the chemically synthesised material epopros-
tenol, necessitated the use of a high pH formulation and ice packs for
its prolonged intravenous use. The development of chemically stable
prostacyclin analogues such as iloprost, treprostinil and beraprost
obviated the requirement for such a formulation [6]. These agents
have been used clinically for different indications, including* Corresponding author at: Centre for Clinical Pharmacology, Division of
Medicine, Floor 3, Rayne Building, University College, 5 University Street, London
WC1E 6JF, UK. Tel.: +44 020 7679 6180; fax: +44 20 7679 6212.
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Open access under CC BY-NC-ND license.pulmonary hypertension, peripheral vascular disease as well as
Raynaud’s phenomenon and digital ulcers associated with scleroder-
ma [7–13]. In particular, iloprost and treprostinil are currently used
extensively in Europe and the US for the treatment of pulmonary
arterial hypertension [14–18].
As with most other mediators, prostaglandins such as prostacy-
clin elicit their molecular, pharmacological and biochemical effects
through binding and activation of speciﬁc receptor sites [19]. It was
initially established by pharmacological techniques that there was a
range of speciﬁc receptors for the naturally occurring prostanoids
(see [20]) and these receptors have been subsequently cloned and
expressed [19,21]. The original classiﬁcation of the different
prostanoid receptors [20,22,23] has remained essentially intact
since the early proposals [24]. Thus, the receptors are identiﬁed as
the IP, EP1, EP2, EP3, EP4, DP (now DP1, see below), FP and TP receptor
[23–25]. The IP, EP2, EP4 and DP1 receptors are classically known to
be Gs-coupled receptors linked to cyclic AMP (cAMP) generation,
while EP1, FP and TP receptors couple to calcium mobilisation
pathways through Gq, Gi and as yet unidentiﬁed G proteins [19,25].
There are several splice variants of EP3 which can couple negatively
or positively to Gi or Gs, respectively [19].
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prostaglandin E2 (PGE2) for the EP receptors, PGF2a for the FP
receptors and thromboxane A2 for the TP receptor [24]. A recent
pharmacological study has suggested evidence for a second IP
receptor on human airway epithelial cells that mediates the
inhibition of cytokine release [26]. This is not thought to be a splice
variant although its occurrence elsewhere has not been described.
The original classiﬁcation of the DP receptor with prostaglandin D2
(PGD2) as the natural ligand has now been designated as DP1 [24].
This takes into account the more recently identiﬁed DP2 receptor or
CRTh2 receptor, that while recognising PGD2, is more closely
associated with chemo-attractant molecules and has no signiﬁcant
homology with the other prostanoid receptors [24].
Despite their extensive clinical use over the past decade, there is
relatively little direct comparative pharmacology of iloprost and
treprostinil in experimental systems and models. It is generally
assumed that both are potent agonists at the prostacyclin IP receptor
and that such agonist activity predominantly underlies their
respective responses, including their potent vasodilator effects in
the pulmonary vasculature, at least under physiological conditions
[27–29]. Indeed, based on this premise, novel agents that are highly
selective agonists at the IP receptor such as the non-prostanoid
moiety, selexipag, are being developed for clinical utilities including
pulmonary hypertension [30,31]. However, the situation is more
complex, since the prostacyclins appear to have functionally
relevant effects at other prostanoid receptors as reviewed by Clapp
and Patel [32].
Although the receptor binding proﬁle of iloprost, including its
high afﬁnity for the IP as well as the EP1, and EP3 receptor, has been
reported for both murine and human prostanoid receptors [21,33],
there has been no reported comparable evaluation of treprostinil.
Because of the multiple pathophysiological processes involved in
pulmonary hypertension, there is a need to understand more about
the respective pharmacology of these two extensively used
prostacyclins. Thus, the current study investigates the binding
proﬁle of treprostinil on human prostanoid receptors, individually
expressed in separate cell lines, and has directly compared this
proﬁle to that of iloprost in the same studies. In addition, the
cellular responses of either an elevation of intracellular cyclic AMP
or calcium levels as appropriate, as a consequence of activation of
the individual human prostanoid receptors by either iloprost or
treprostinil, have also been evaluated.
2. Methods and materials
2.1. In vitro radio-ligand binding assays
Evaluation of the afﬁnities of treprostinil and iloprost for each
prostanoid receptor was determined in radioligand binding assays
using standard techniques. Cell lines, conditions and materials
used are documented in Table 1 and broadly follow protocolsTable 1
Experimental conditions for prostanoid receptor radioligand binding assays. h = human
kidney 293 cells; CHO = Chinese hamster ovary; 1321N1 = human glial brain astrocytom
Prostanoid receptor Expression system/accession no. Ligand Conce
IP (h) HEK-293/NM_000960 [3H] iloprost 10 
EP1 (h) HEK-293/NM_000955 [
3H] PGE2 1.5 
EP2 (h) HEK-293/NM_000956 [
3H] PGE2 3.0 
EP3 (h) HEK-293/NM_198714 [
3H] PGE2 0.5 
EP4 (h) CHO/NM_000958 [
3H] PGE2 0.5 
DP1 (h) 1321N1/NM_000953.1 [
3H] PGD2 1.5 
FP (h) HEK-293/NM_000959 [3H] PGF2a 2 
TP (h) (TXA2) HEK-293/U11271 [
3H] SQ 29548 5 previously described [21,34,35]. Brieﬂy, cells from each cell line
stably expressing the recombinant human prostanoid receptor
were spun down at 4 8C and the cell pellet suspended in a 50 mM
Tris/HCl (pH 7.4) buffer containing 5 mM EDTA, 20 mm NaCl, 5 mM
KCl, 5 mM MgCl2, 1.5 mM CaCl2, 10 mg/ml trypsin inhibitor, 1 mg/
ml leupeptin and 75 mg/ml phenylmethylsulphonyl ﬂuoride.
Cell lysis was performed by ultra sonication (3 min at 4 8C)
using a Vibro cell 72405, followed by centrifugation (Beckman
Avanti J30I) of the resulting homogenate at 4 8C (50,000  g for
15 min). The membrane pellet was resuspended in fresh Tris buffer
containing 10% glycerol and stored as aliquots at 70 8C until used
in the binding studies. Proteins levels were determined using the
Bradford method and the optimised quantity of protein used in the
binding studies was 16 mg for the TP receptor, 20 mg for the EP2,
EP3, EP4 and FP receptors, 40 mg for the IP receptor and 60 mg per
sample for the EP1 and DP1 receptors. Incubations were carried out
using nanomolar concentrations of the appropriate [3H] radioli-
gand (Table 1) in the absence or presence of various concentrations
of the prostacyclin analogue (ﬁnal solvent concentration was kept
constant). Total binding was determined in the presence of vehicle.
Non-speciﬁc binding was determined in the presence of 650–
5000-fold excess of the corresponding non-labelled ligand.
Following a 60–120 min incubation of ligands at room tempera-
ture (Table 1), samples were ﬁltered rapidly under vacuum
through glass ﬁbre ﬁlters, dried, and then counted for radioactivity
in a scintillation counter.
The speciﬁc ligand binding was calculated as the difference
between total binding measured in the presence of radioligand
alone and nonspeciﬁc binding determined in the presence of an
excess of unlabelled ligand, as performed in the laboratory at Cerep
(Le bois l’Eveˆque, France). Speciﬁc binding for ligands reached
equilibrium after 30–40 min of incubation at room temperature,
was stable for greater than 2 h and was determined to be saturable.
Results are expressed as a percent of the control speciﬁc binding
obtained.
Competition curves for each data-set were generated by non-
linear regression analysis of the data (Prism 4.03; GraphPad, San
Diego, USA) using a four parameter logistic (Hill) equation:
Y ¼ D þ ðA  DÞ
ð1 þ 10ðXlog IC50ÞnHÞ
(1)
where Y = speciﬁc binding, D = minimum speciﬁc binding,
A = maximum speciﬁc binding, IC50 = the concentration that
inhibits half of the control speciﬁc binding and nH = Hill factor.
The inhibition constants (Ki) were calculated using the Cheng
Prusoff equation:
K i ¼
IC50
1 þ ðL=KDÞ (2); Kd = dissociation constant; RT = room temperature; HEK-293 = human embryonic
a.
ntration (nM) Kd (nM) Nonspeciﬁc (mM) Incubation time @RT (min)
8 Iloprost (10) 60
1.5 PGE2 (10) 120
3.0 PGE2 (10) 120
0.8 PGE2 (1) 120
0.3 PGE2 (10) 120
1.2 BW245C (1) 60
3.8 Cloprostenol (10) 60
4 U44069 (10) 60
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nity of the radioligand for the receptor. Scatchard analysis was
used to determine KD from a plot of speciﬁc binding/free
radioligand concentration versus speciﬁc binding giving a slope
equivalent to 1/KD and are given in Table 1 (see Figure S1 of
Supplementary Information for examples of Scatchard plots).
2.2. Receptor activation assays
2.2.1. Cyclic AMP assay
HEK 293 (expressing EP2, EP4) CHO (EP3, IP) or 1321N1 (DP1)
cells were lifted with a non-enzymatic cell stripper and re-
suspended in assay buffer at the desired cell density for each cell-
line. Cyclic AMP was assayed in suspension of cells using a CisBio
HTRF cAMPHiRange Kit (Cisbio US, Bedford, MA, USA) according to
the manufacturer’s protocol. Cells were incubated with the
prostacyclin analogues for 20 min at 37 8C. The reaction was
terminated by sequentially adding D2-labelled cyclic AMP and
cryptate-labelled anti-cyclic AMP antibody contained in lysis
buffer. The plate was incubated at room temperature for 60 min
before reading of ﬂuorescent emissions at 620 nm and 668 nm
with excitation at 314 nm were made on a microplate reader
(Molecular Devices, Sunnyvale, CA, USA). These experiments were
performed in the laboratory at Multispan (Hayward, CA, USA). Data
were converted from a cyclic AMP standard curve and expressed as
cyclic AMP (nM).
2.2.2. Calcium mobilization
HEK293 cells expressing FP, TP or EP1 receptors were seeded in
384-well plates at appropriate densities and cultured overnight.
The calcium ﬂux assay was conducted according to the manu-
facturer’s protocol using the FLIPR Calcium 4 Assay Kit (R8142;
Molecular Devices). Loading buffer, containing the calcium-
sensitive dye, was added to the cells and incubated for 60 min
at 37 8C. The plate was then transferred to a FlexStation1 3
benchtop multi-mode microplate reader (Molecular Devices),
where compounds were automatically injected into each well.
Intracellular calcium, monitored as changes in ﬂuorescent, was
recorded for 90 s with a single compound application occurring
after 19 s. These experiments were performed in the laboratory at
Multispan (Hayward, CA, USA). Assay results (5–10 determinations
per analogue concentration) were plotted as relative ﬂuorescence
units (RFU).
2.3. Materials
Treprostinil was provided in powder form by United Therapeu-
tics Corporation (Research Triangle Park, NC, USA). Iloprost (50:50
R/S isomer), BW245C, prostaglandin E2 (PGE2) and PGD2 were
purchased from Cayman Chemical Company (Ann Arbor, MI, USA).
Cloprostenol, U-44069 and buffer reagents and materials were
purchased from Sigma–Aldrich (Lyon, France). Treprostinil was
dissolved in DMSO at a stock concentration of 10 mM and iloprost
was dissolved in methylacetate at a concentration 13.9 mM. For
concentration–response experiments, the highest agonist concen-
tration used was 10 mM with serial 1:10 dilutions.
In binding assays, stable cells expressing respective human
prostanoid receptors were used by Cerep (Table 1). The radi-
oligands used in these studies (Table 1) were obtained from Perkin
Elmer NEN (Courtaboeuf, Cedex 191945, France), or for iloprost,
from Isobio (Fleurus, Belgium). Likewise for functional assays
conducted in the laboratories of Multispan, stable cell lines
expressing human receptors were: EP1 (GenBank accession
number NM_000955.2; Cat# C1201a) in HEK293T, EP2 (GenBank
Accession Number NM_000956.3; Cat# C1202) in HEK293T, EP3
(GenBank Accession Number NM_000957; Cat# C1203-1a), inCHO-K1, EP4 (GenBank Accession Number NM_000958; Cat#
C1204) in HEK293T, FP (GenBank Accession Number NM_000959;
Cat# C1205) in HEK293T, IP (GenBank Accession Number
NM_000960; Cat# C1206-1) in CHO-K1, DP1 (GenBank Accession
Number NM_000953; Cat# C1200) in HEK293T and TP (TXA2R;
GenBank Accession Number NM_001060.4; Cat# C1365) in
HEK293T were from Multispan.
2.4. Data analysis
In binding studies, IC50 values were obtained from each
individual concentration–response curve for speciﬁc binding
(n = 6) and used to determine the afﬁnity constant, Ki.
Concentration-dependent relationships for each prostacyclin
analogue stimulating elevations in either intracellular cyclic AMP
or calcium (mean  S.E.M. of n determinants per concentration as
indicated) as appropriate, were constructed using a variable slope
sigmoidal ﬁtting routine in GraphPad Prism 4.03 (San Diego, CA, USA).
The EC50 value, the concentration of agonist causing 50% of the
maximal response (Emax), was determined from individual ﬁts to each
data-set and expressed as mean  S.E.M. Statistical analysis was
performed using GraphPad with signiﬁcance assessed using a
Student’s t-test or ANOVA with correction for multiple comparisons.
A P value <0.05 was considered signiﬁcant.
3. Results
3.1. Radioligand binding data
The data obtained from the competition binding assays with the
tritiated ligands in the presence of either iloprost (1011 to 105 M)
or treprostinil (1011 to 105 M) for the eight recombinant human
prostanoid receptors studied, the IP, EP1, EP2, EP3, EP4, DP1, FP and
TP receptor, are shown in Fig. 1. Both iloprost and treprostinil
yielded concentration-dependent reductions in speciﬁc binding for
each of the receptor types over the range of concentrations
evaluated. However, neither prostacyclin analogue yielded a full
speciﬁc binding curve for the TP receptor because of the high
concentrations (>10 mM) that would have been required to reach
full displacement of radioligand (Fig. 1). The derived afﬁnity
constant, the Ki value, for either iloprost or treprostinil at each
prostanoid receptor, is given in Table 2. To aid comparison of this
data to that obtained from earlier human prostanoid receptor
assays, the Ki values reported for iloprost from the work of
Abramovitz and colleagues [21], are also presented in Table 2.
The data from the current study shown in Table 2 indicate that
iloprost has high binding afﬁnities for the IP and EP1 receptors,
though this was signiﬁcantly (P = 0.002) greater for the EP1
receptor, as indicated by the lower Ki value. Its afﬁnity for the FP,
EP3 and EP4 receptors was some two log orders lower and was even
lower for the DP1, EP2 and TP receptors (Table 2).
In general, the overall binding proﬁle to the prostanoid receptors
obtained in the current work with iloprost was similar to that
previously reported for iloprost against human prostanoid receptors
(see Table 2; data from Ref. [21]). Comparison of the Ki values in
Table 2 indicates that the order of afﬁnity for iloprost in the current
work was EP1 > IP >> FP > EP3 = EP4 > DP1 > EP2 > TP, while that
reported previously by Abramovitz and colleagues [21] was
EP1 = IP > EP3 > EP4 > FP > DP1 > EP2 > TP. Thus, the main differ-
ence found between the two studies utilising iloprost was the
ranking of the Ki for the FP receptor.
The prostanoid receptor binding proﬁle for treprostinil differed
from that observed with iloprost (Table 2). Treprostinil had a high
and similar afﬁnity for the DP1 and EP2 receptor, which was some
10-fold (P < 0.01, one way ANOVA) greater than that for the IP
receptor. It had a much lower afﬁnity for the EP1 receptor, weaker
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Fig. 1. Competition binding assays for different recombinant human prostanoid receptors. Receptors were stably expressed in HEK-293 (IP, EP1, EP2, EP3, TP, FP), CHO (EP4) or
1321N1 (DP1) cell lines. The total speciﬁc and non-speciﬁc binding was determined for each [3H] ligand as per methods and equilibrium competition binding assays
performed in the presence of 0.01–10,000 nM of either iloprost or treprostinil. Data are shown as mean  S.E.M. of 6 individual determinations performed on two separate
occasions. Statistical analysis using 2-way ANOVA indicated that differences in binding afﬁnity curves existed between treprostinil and iloprost for the IP, EP1, EP2 EP3 DP1, FP
(P < 0.001) but not EP4 (P = 0.08) receptor.
B.J. Whittle et al. / Biochemical Pharmacology 84 (2012) 68–75 71afﬁnity for the EP4 receptor, and very weak afﬁnity for EP3, FP and
TP receptors (Table 2). Thus, the rank order of afﬁnity of
treprostinil for the human prostanoid receptors based on the
derived Ki values was DP1 = EP2 > IP > EP1 > EP4 > EP3 > FP > TP.
In the current work, the Ki values at the IP receptor showed a 10-
fold difference (P < 0.001, unpaired t-test) in afﬁnity between
iloprost and treprostinil. The major difference between the overall
binding proﬁle of iloprost and treprostinil for Gs-coupled receptors
was the high afﬁnity of treprostinil for the DP1 and EP2 receptor.
This was reﬂected by the 230-fold and 325-fold lower Ki value
obtained in the current study for the DP1 and EP2 receptor
respectively with treprostinil compared with iloprost. Treprostinil
had a higher Ki than iloprost at the EP4 receptor, though overall theTable 2
Prostanoid receptor binding proﬁles for treprostinil and iloprost. Speciﬁc binding
was determined using displacement radioligand binding in cell membranes over
expressing recombinant human prostanoid receptors. Values of the inhibition
constant, Ki are shown as the mean  S.E.M. of 6 individual determinations obtained
on two separate occasions. The Ki for iloprost at the EP1 receptor was signiﬁcantly
(P < 0.002) greater than that for the IP receptor, and its Ki for IP receptor was
signiﬁcantly (P < 0.001) greater than the Ki of treprostinil at this receptor. For
comparison, the table also contains Ki values for iloprost obtained from historical
binding data published by Abramovitz et al. for human prostanoid receptors expressed
in HEK 293 (EBNA) cells [21]. NC = not calculable.
Receptor Radioligand binding assay Abramovitz et al. [21]
Treprostinil Ki (nM) Iloprost Ki (nM) Iloprost Ki (nM)
IP 32.1  0.2 3.9  0.6 11  1
EP1 212  56 1.1  0.3 11  1
EP2 3.6  0.3 1172  159 1870  176
EP3 2505  263 208  26 56  6
EP4 826  116 212  27 284  9
DP1 4.4  0.4 1016  63 1035  171
FP 4680  927 131  17 619  159
TP NC 3778  375 6487  29speciﬁc binding curves were not signiﬁcantly different (P = 0.08, 2-
way ANOVA). These binding studies also indicted that treprostinil
had a 200-fold lower afﬁnity for the EP1 receptor than did iloprost,
as well as a much lower afﬁnity for the FP and TP receptor (Table 2).
3.2. Prostanoid receptor activation studies
Studies on the effect of iloprost or treprostinil over a wide
concentration range (1012 to 105 M) on functional responses in
cells expressing each prostanoid receptor were conducted. The
concentration–response curve for each prostacyclin analogue
against each prostanoid receptor is shown in Fig. 2, the responses
being determined, depending on the receptor under investigation,
as an elevation of intracellular cyclic AMP or calcium inﬂux (Fig. 2).
Typical sigmoid curves were obtained for all but one of the
prostanoid receptors with either analogue (Fig. 2). The exception
was iloprost at the DP1 receptor, which unlike in the binding study,
showed an atypical sigmoidal relationship with a shallow slope,
the response at 10 mM being comparable to the maximal response
to treprostinil, achieved at 10 nM (Fig. 2). From the concentration–
response data obtained for each prostanoid receptor, the EC50 was
calculated and shown in Table 3.
The rank order of iloprost potency for evoking a response in
cells expressing each particular prostanoid human receptor was
EP1 = IP > EP3 > FP > EP4 > TP > DP1 = EP2, which is broadly simi-
lar to the ranking observed in the binding studies. Thus, iloprost
had high activity at both the IP and the EP1 receptor in the
expression system used and indeed had a similar EC50 value for
activity (sub nanomolar) at either receptor. Furthermore, iloprost
was 75-fold less active at the EP3 receptor than at the IP receptor,
500–1000-fold less active at the FP and EP4 receptor and had EC50
values in the micromolar range for activity at the EP2, DP1, and TP
receptors (Table 3).
As with the radioligand binding studies, iloprost had higher
activity in evoking a functional response in cells expressing the IP
receptor than did treprostinil, having a 5-fold (P < 0.01, unpaired
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Fig. 2. Receptor activation assays in cells stably expressing human prostanoid receptors. Concentration-dependent increases in intracellular cyclic AMP (IP, EP2, EP3, EP4, DP1
receptors) or calcium (EP1, FP, TP) were measured upon treatment with either treprostinil or iloprost (0.001–10,000 nM) for 1 h. Data are shown as mean  S.E.M. of 5–10
determinations performed on 2–3 separate occasions. Curves have been generated from ﬁtting data to a variable slope sigmoidal function. Statistical analysis using 2-way ANOVA
indicated that differences in concentration response curves existed between treprostinil and iloprost for the IP, EP1, EP2 DP1, FP, TP (P < 0.001) but not EP3 and EP4 (P > 0.9) receptor.
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curve signiﬁcantly shifted (P < 0.001, 2-way ANOVA) to the left
(Fig. 2).
By contrast to the proﬁle of iloprost, the rank order for evoking a
response with treprostinil in cells expressing each separate
receptor was DP1  IP > EP2 > EP3 > EP4 > EP1 > TP > FP, again
in general agreement with the rank order for the radioligand
binding studies. Thus, treprostinil had high potency in activating
DP1 and EP2 receptors as well as the IP receptor. From comparison
of the EC50 values, it was some 36-fold less active at the EP3
receptor, 95-fold less active at the EP4 and 150-fold less active at
the EP1 site than at the IP receptor. As can be seen from Table 3,
treprostinil had little activity at the FP or TP receptor sites.Table 3
Receptor activation assays in cells stably expressing human prostanoid receptors.
For IP, EP2, EP3, EP4 and DP1 receptor activation assays, concentration-dependent
intracellular cyclic AMP accumulation was measured upon treatment with either
treprostinil or iloprost. For FP, TP and EP1 receptor activation assays, concentration-
dependent increases in intracellular calcium were measured upon prostacyclin
analogue treatment. The concentration of agonist causing 50% of the maximal
response, the EC50 value, were determined from the concentration–response curves
(5–10 determinations per drug concentration performed on to 2–3 separate
occasions) and shown as the mean  S.E.M. The EC50 values for iloprost at the IP and
EP1 receptor were not signiﬁcantly different (P = 0.6, unpaired t-test); the EC50 values at
the DP1 receptor for iloprost and treprostinil were signiﬁcantly different (P < 0.02,
unpaired t-test).
Receptor Treprostinil EC50 (nM) Iloprost EC50 (nM)
IP 1.9  0.4 0.37  0.10
EP1 285  143 0.3  0.1
EP2 6.2  1.2 2094  560
EP3 68.9  7 27.5  0.5
EP4 181  37 389  86
DP1 0.6  0.1 2059  765
FP >3500 191  44
TP 919  110 1417  1414. Discussion
The current study has compared the activity of two clinically
used prostacyclin analogues, iloprost and treprostinil, in receptor
binding assays and in biochemical functional responses using cells
stably expressing individual human prostanoid receptors. The
prostanoid receptors investigated were those classiﬁed as IP, EP1,
EP2, EP3, EP4, DP1, FP and TP [23,24]. Substantial differences in the
proﬁle of activity between these prostacylins have now been
identiﬁed, the key ﬁndings being that unlike iloprost, treprostinil is
a potent agonist at both the DP1 and EP2 receptor, while having
little activity at the EP1 receptor.
Previous work has reported on the binding of iloprost to these
human prostanoid receptors [21], and it was reassuring that the Ki
values and rank order of afﬁnity derived from the current work is
comparable. A Ki value of 11 nM for iloprost at the human IP
receptor in that previous work, and 4 nM in the current study, are
also similar to the Ki of 4 nM for iloprost at this receptor in another
report [36]. Moreover, studies on the binding of iloprost to murine
IP receptors gave a Ki value of 11 nM [33]. As described previously
for both murine and human prostanoid receptors [21,33], iloprost
also had high afﬁnity for the human EP1 receptor. Indeed, in the
current work, the Ki value for the EP1 receptor was even lower
(1 nM) than for the IP receptor. Likewise, other radioligand binding
studies have reported high afﬁnity binding with iloprost for the
human EP1 receptor, with a Ki not signiﬁcantly different from the
natural ligand, PGE2 [37].
Iloprost had a relatively low afﬁnity for the human FP or EP4
receptor, and even lower afﬁnity for the EP2, DP1 or TP receptor in
the current study, comparable to that found previously in
radioligand binding studies on both murine and human prostanoid
receptors [21,33]. In the former two studies however, iloprost did
have signiﬁcant afﬁnity for the murine or human prostanoid EP3
binding site, but this was less pronounced in the current work
using the human EP3 receptor. As the EP3 receptor is known to
exhibit a range of splice variants for both murine and human
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values obtained in these assays.
Findings on the relative afﬁnities for the different prostanoid
receptors in the binding assay were generally translated to activity
in the biochemical functional assays utilised in the present work.
Thus, iloprost had high activity in stimulating cyclic AMP levels in
the cells expressing the human IP receptor or in stimulating
calcium inﬂux in cells expressing the EP1 receptor; indeed the EC50
values for these responses were the same (0.35 nM, Table 2).
Earlier pharmacological studies using a range of isolated smooth
muscle bioassay preparations also concluded that iloprost has
potent activity at both the IP and EP1 receptor [25,38,39].
In the present biochemical functional assays, iloprost also
activated the human EP3 receptor to elevate intracellular cyclic
AMP levels, although the EC50 value was some 75-fold higher
than that required to activate the response in cells expressing
the IP receptor. Iloprost was less active on the cells expressing
the FP or EP4 receptor, and very much less active in eliciting a
response in cells expressing the TP, EP2 or DP1 receptors. Earlier
work in cells expressing either the human EP2 or EP4 receptor
has also shown iloprost be a very weak agonist in terms of its
ability to elevate cyclic AMP in such cells [40]. Recent studies in
HEK-293 cells over-expressing EP2 receptors also showed
iloprost failing to elevate intracellular cyclic AMP [26]. However,
iloprost had some activity in cells over-expressing the EP4
receptor, and partial agonist activity in cells over-expressing the
DP1 receptor, with Wilson and colleagues [26] concluding that
the latter receptor may be activated at high concentrations of
iloprost. In the current study and in all previous work, iloprost
likewise had very low activity on the DP1 receptor expressed in a
number of different cell systems including human platelets and
COS-M6 cells [21,41,42].
In the present work, treprostinil exhibited a very different
proﬁle in the radioligand binding assays for the human prostanoid
receptors when compared to iloprost. Thus, unlike iloprost,
treprostinil had a high afﬁnity for both EP2 and DP1 receptors in
the binding assay, which was surprisingly, some 10-fold greater
than that for the IP receptor. On the other hand, treprostinil had a
200-fold lower afﬁnity for the EP1 receptor compared with iloprost,
and the afﬁnity for the EP3 and FP receptors was in the low to mid
micromolar range as opposed to the nanomolar range for iloprost.
Afﬁnity for the EP4 receptor was low for treprostinil and iloprost,
and both had minimal afﬁnity for the human TP receptor.
The rank order of activity of treprostinil in evoking changes in
either cyclic AMP or intracellular calcium levels in the cells
expressing the individual human prostanoid receptors was
comparable to that found in the radioligand binding assays. Thus,
treprostinil elevated cyclic AMP with a similar high potency in cells
expressing either the IP or DP1 receptor, and its activity on cells
with the EP2 receptor was also high. Other work assessing
prostanoid receptor antagonists in murine alveolar macrophages
has suggested that treprostinil acts on EP2 receptors to inhibit
phagocytosis and cytokine release [43]. In the current work,
treprostinil was less active on cells expressing the human EP3 or
the EP4 receptor, and poorly active on the EP1 receptor, with very
low activity on the TP and FP receptors.
As with the binding studies, the high activity of iloprost at the
EP1 receptor site along with the ﬁnding that treprostinil had high
afﬁnity and potent activity at the DP1 and EP2 sites, are the key
differences in the proﬁles of these two prostacyclin analogues.
Interestingly, from a phylogenic perspective, the EP2, DP1 and IP
receptor are the most highly related receptors within one of two
subgroups of prostanoid receptors [41,44]. Such potent activity of
treprostinil at the DP1 receptor provides a novel aspect to
interpreting pharmacological activity of this prostacyclin ana-
logue, as activation of the DP1 receptor will lead to bothvasodilatation and inhibition of human platelet aggregation, as
does IP receptor activation [45,46].
In terms of pharmacological responses that could underlie
the therapeutic beneﬁt of these prostacyclin analogues in the
clinical treatment of pulmonary hypertension, studies on human
pulmonary vascular tissue are clearly important. It is known
from studies utilising pharmacological agonists and antagonists
that the prostanoid receptors involved in the relaxation of
human pulmonary venous preparations in vitro are the DP1 and
IP receptors, and to a lesser extent the EP4 receptor [47,48]. In
human pulmonary artery preparations however, the IP receptor
appears to be the predominant receptor involved in relaxation
[47]. Additional studies have indicated that the prostanoid
receptors involved in the contraction of human isolated
pulmonary veins were the EP1 and TP receptor [49]. Indeed,
EP1 receptors are expressed in human pulmonary veins, as
demonstrated by immunohistochemistry [48]. Earlier pharma-
cological work had also suggested that EP3 receptor agonists had
potent contractile activity on the human isolated pulmonary
artery [50].
It is not yet known whether the high afﬁnity and potency of
iloprost for the EP1 receptor will lead to vasoconstriction and
oppose the vasodilatation evoked through IP receptor activation in
arteries or veins. This will depend on factors such as the relative
density and distribution of the EP1 and IP receptor in these tissues,
especially human pulmonary vasculature. There is however, some
evidence that activation of the EP3 receptor, which like EP1
receptor activation elicits vasoconstriction, can offset the vasodi-
lator response to IP receptor activation by iloprost in rat small
pulmonary arteries in vitro [51]. In other studies, EP3 or EP1
receptor activation has been suggested to limit the relaxant
activity of prostacyclin analogues in guinea-pig aorta [52] or rabbit
iliac artery [53]. Moreover, the vasorelaxant actions of both
iloprost and treprostinil in rat tail artery was enhanced to a small
but signiﬁcant degree by an antagonist at the EP3 receptor,
suggesting a functional antagonism with IP receptors in this tissue
[54].
Apart from the potential opposing functional interactions
between the vasodilator and vasoconstrictor response following
prostanoid receptor activation, there is the possibility of additive
or synergistic effects through simultaneous activation of the
different Gs-coupled prostanoid receptors, which theoretically
could enhance the therapeutic efﬁcacy of the prostacyclins.
Iloprost has relatively poor afﬁnity for the EP4 receptor that can
evoke vasodilatation in human vascular tissue [48,55], and even
less afﬁnity for the DP1 and EP2 receptors, that along with the IP
receptor, are primarily involved in the pulmonary vasodilator
response to prostanoids [56]. Therefore, additive or synergistic
effects of iloprost at prostanoid receptors evoking vasodilatation, is
unlikely. In contrast, the high afﬁnity and activity of treprostinil at
the human DP1 and EP2 receptors in addition to the IP receptor
could synergise to potently evoke a vasodilator response, while the
minimal activity of treprostinil at EP1 receptors would not be
expected to produce an opposing vasoconstriction. This proﬁle
suggests that treprostinil could have a comparatively preferential
vasodilator proﬁle in vascular tissue, particularly in the human
pulmonary circulation.
The difference in the pharmacological proﬁle between iloprost
and treprostinil in some models may hence reﬂect activity at
multiple prostanoid receptor sites. Thus in human pulmonary
arterial smooth muscle cells, treprostinil evoked a full dose-
dependent elevation of intracellular cyclic AMP, whereas iloprost
was less potent and reached a far lower maximal response [57].
Whether this reﬂected (a) activation by treprostinil of multiple
prostanoid receptors coupled to Gs compared with iloprost (b) that
iloprost was only a partial agonist at these sites, (c) that the
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EP1 and EP3 receptor activation or (d) a combination of the above, is
not known.
The disparity of the proﬁle between iloprost and treprostinil
at the various prostanoid receptors will have importance when
determining the overall pharmacological events that they
initiate, especially when used to treat disease. This could also
contribute to any differences in the degree of side-effects of
these prostacyclins in clinical use, including those exerted on
the gastro-intestinal tract. Under physiological conditions, both
analogues are potent agonists at the IP receptor, which may
dominate the nature of the overall pharmacological responses in
vascular tissue. However, it has been demonstrated clearly in
two studies using human pulmonary tissue, that in idiopathic
pulmonary arterial hypertension, the expression of the IP
receptor is down-regulated when compared to control tissue,
as detected by both immunoblotting and immunohistochemical
techniques [29,58]. Under such conditions of low IP receptor
density or stimulus-coupling activity, the pharmacological
responses of either iloprost or treprostinil through IP receptors
could potentially be compromised. Indeed, in a rat model of
pulmonary hypertension where almost complete down-regula-
tion of the IP receptor was observed, it was suggested that
iloprost may act through another vasodilator receptor, the EP4
receptor, as this was not similarly down-regulated [58]. The
expression of the EP4 receptor has been detected in human
pulmonary vein using immunohistochemical techniques [48].
However, the relatively poor afﬁnity and activity of iloprost at
the human EP4 receptor suggests that activation of this receptor
is unlikely to occur in the therapeutic dosing range of
iloprost, the upper plasma concentrations achieved with
intravenous administration in humans for example, being less
than 1 nM [59].
Should expression of IP receptors be sufﬁciently down-
regulated in pulmonary vascular disease to reduce efﬁcacy at
the IP receptor, treprostinil could have the capacity to act on the
other key vasodilator prostanoid receptors in the lung, namely the
DP1 receptor and the EP2 receptor. As treprostinil has high afﬁnity
and activity at these latter prostanoid receptors, such positive
interactions should be achieved within the same clinical dose
range that affects IP receptors, with plasma concentrations of
treprostinil in patients treated by intravenous or subcutaneous
routes ranging from 2.5 to 25 nM [60]. This would require that
unlike the IP receptor, the DP1 and EP2 prostanoid receptors were
not similarly down-regulated in human pulmonary vascular
disease. Interestingly, EP2 receptor expression in pulmonary
arterial smooth muscle cells did not appear to be affected by
monocrotaline treatment that produced experimental pulmonary
hypertension in rats [58], though its effects on DP1 expression were
not monitored.
The importance of the differential prostanoid receptor
agonist proﬁle of iloprost and treprostinil will therefore become
clearer with further knowledge of the pathology of this disease,
particularly as regards to changes in IP and other prostanoid
receptor expression or desensitisation and their coupled
functional activity in the pulmonary vasculature. Moreover,
consideration of pharmacological actions other than the
vasoactive properties of the prostacyclins is warranted. Thus,
the degree of involvement of IP receptor or other receptor
activation in the processes limiting the characteristic exagger-
ated vascular smooth muscle proliferation in pulmonary
hypertension requires careful evaluation [28,29]. All such
information may guide the eventual selection, based on its
pharmacological proﬁle, of a particular prostacyclin analogue or
IP agonist for the various aetiologies that comprise the spectrum
seen in pulmonary hypertensive patients.Acknowledgments
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